| Nevada                                                                  | 88-0507007                                |
|-------------------------------------------------------------------------|-------------------------------------------|
| (State      or other jurisdiction ofincorporation      or organization) | (IRS      Employer Identification Number) |

| Securities      registered pursuant to Section 12(b) of the Act: | None |
|------------------------------------------------------------------|------|

|   | Securities      registered pursuant to Section 12(g) of the Act:  $.001 Par      Value Common Stock |
|--------|---------------------------------------------------------------------------------------------------------------|

----

|   | ONCOLIN      THERAPEUTICS, INC. |
|--------|---------------------------------|

|   | (pka      EDGELINE HOLDINGS, INC.) |
|--------|------------------------------------|

|          |          |                                                                                                                                                               | Page      No.  |
|---------------|---------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|
| Part      I   | Item      1.  | Description      of Business                                                                                                                                       |        4  |
|          | Item      2.  | Description      of Property                                                                                                                                       |        13 |
|          | Item      3.  | Legal      Proceedings                                                                                                                                             |        13 |
|          | Item      4.  | Submission      of Matters to a Vote of Security Holders                                                                                                           |        13 |
|          |          |                                                                                                                                                               |           |
| Part      II  | Item      5.  | Market      for Common Equity, Related Stockholder Matters and Small Business Issuer      Purchases of Equity Securities                                           |        14 |
|          | Item      6.  | Management’s      Discussion and Analysis or Plan of Operations                                                                                              |        15 |
|          | Item      7.  | Financial      Statements                                                                                                                                          |        18 |
|          | Item      8.  | Changes      in and Disagreements with Accountants on Accounting      and Financial Disclosure                                                                |        28 |
|          | Item      8A. | Controls      and Procedures                                                                                                                                       |        28 |
|          | Item      8B. | Other      Information                                                                                                                                             |  28       |
|          |          |                                                                                                                                                               |           |
| Part      III | Item      9.  | Directors,      Executive Officers, Promoters and Control Persons, and      Corporate Governance; Compliance with Section 16(a) of      the Exchange Act |        29 |
|          | Item      10. | Executive      Compensation                                                                                                                                        |        30 |
|          | Item      11. | Security      Ownership of Certain Beneficial Owners and Management      and Related Stockholder Matters                                                           |        31 |
|          | Item      12. | Certain      Relationships and Related Party Transactions, and Director      Independence                                                                     |        32 |
|          | Item      13. | Exhibits                                                                                                                                                           |        33 |
|          | Item      14. | Principal      Accountant Fees and Services                                                                                                                        |        34 |

----

----

----

| ·   | performance      of satisfactory preclinical laboratory and animal studies under the FDA’s      good laboratory practicesregulations; |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | obtaining      the approval of independent Institutional Review Boards at each clinical      site to protect the welfare and rights of human subjects in clinical      trials; |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | submission      to and acceptance by the FDA of an Investigational New Drug Application      (IND) which must become effective before human clinical trials may begin      in the United States; |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | successful      completion of a series of adequate and well-controlled human clinical      trials to establish the safety, purity, potency and effectiveness of any      product candidate for its intendeduse; |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | submission      to, and review and approval by, the FDA of a marketing application (NDA)      prior to any commercial sale or shipment of a product;  and |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | development      and demonstration of manufacturing processes which conform to FDA-mandated      current good manufacturingpractices. |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------|

| ·   | further      identify any possible adverse side effects and safety    risks; |
|--------------------|------------------------------------------------------------------------------|

| ·   | assess      the preliminary or potential effectiveness of the product candidate for      the specific targeted disease or medical condition;  and |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | assess      dosage tolerance and determine the optimal dose for a Phase III      trial. |
|--------------------|-----------------------------------------------------------------------------------------|

----

----

----

divest ourselves ofproducts or businesses that 
may no longer be a strategic fit toour business strategy.

| ·   | outsourcing      the formulation and manufacture of ourproducts; |
|--------------------|------------------------------------------------------------------|

| ·   | undertaking      lengthy clinical trials; |
|--------------------|-------------------------------------------|

| ·   | participating      in regulatory approval processes;and |
|--------------------|---------------------------------------------------------|

| ·   | conducting      sales and marketing activities. |
|--------------------|-------------------------------------------------|

----

| ·   | seek      regulatory approvals for our productcandidates; |
|--------------------|-----------------------------------------------------------|

| ·   | develop,      formulate, manufacture and commercialize our drugs; implement additional      internal systems and infrastructure; and hire additional clinical and      scientific personnel; and |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | expect      to experience negative cash flow for the foreseeable future as we fund our      operating losses and capital expenditures. As a result, we will need to      generate significant revenues to achieve and maintain profitability. We      may not be able to commercialize products from which to generate these      revenues, and we may never achieve profitability in the      future. |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | continued      scientific progress in our research and development    programs; |
|--------------------|---------------------------------------------------------------------------------|

| ·   | the      magnitude of our research and development  programs; |
|--------------------|---------------------------------------------------------------|

| ·   | progress      with preclinical testing and clinicaltrials; |
|--------------------|------------------------------------------------------------|

| ·   | the      time and costs involved in obtaining regulatory  approvals; |
|--------------------|----------------------------------------------------------------------|

| ·   | the      costs involved in filing and pursuing patent applications and enforcing      patent claims; |
|--------------------|------------------------------------------------------------------------------------------------------|

| ·   | competing      technological and marketdevelopments; |
|--------------------|------------------------------------------------------|

| ·   | the      establishment of additional strategicalliances; |
|--------------------|----------------------------------------------------------|

| ·   | the      cost of commercialization activities and arrangements;  and |
|--------------------|----------------------------------------------------------------------|

| ·   | the      cost of product licensing and any possible  acquisitions. |
|--------------------|--------------------------------------------------------------------|

|  Percent      Below  Current Market Price |   |  Price      Per Share(1) |   |  Number      of Shares Issuable (2) |   | Shares      Outstanding After Issuance (3) |   | Percent      of Outstanding Shares(4) |
|----------------------------------------------------------|--------|-------------------------------|--------|------------------------------------------|--------|--------------------------------------------|--------|---------------------------------------|
| 0%                                                       |   | $0.29                         |   | 34,265,351                               |   | 82,896,083                                 |   | 41.35%                                |
| 10%                                                      |   | $0.26                         |   | 38,072,612                               |   | 86,703,344                                 |   | 43.91%                                |
| 25%                                                      |   | $0.20                         |   | 50,763,483                               |   | 99,394,215                                 |   | 51.07                                 |
| 50%                                                      |   | $0.10                         |   | 101,526,966                              |   | 150,157,698                                |   | 67.61                                 |

| (1)   | Represents      purchase prices equal to 96% of $0.30, the closing bid price of the      Company’s common stock on March 10, 2008, and potential reductions thereof      of 10%, 25% and 50%. |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (2)   | Represents      the number of shares issuable if the entire $10,000,000 commitment under      the equity line of credit was drawn down at the indicated purchase      prices. |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (3)   | Based      on 48,630,732 common shares issued and outstanding on March 14,      2008. |
|-----------------|---------------------------------------------------------------------------------------|

| (4)   | Percentage      of the total outstanding shares of common stock after the issuance of the      shares indicated which would be owned by Dutchess, without considering any      contractual restriction on the number of shares the selling stockholder      may own at any point in time, other restrictions on the number of shares      the Company may issue or issuance of shares under any of its other      convertible or exchangessecurities. |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| ·   | the      accuracy of the assumptions underlying our estimates for capital needs in      2008 and beyond; |
|--------------------|----------------------------------------------------------------------------------------------------------|

| ·   | scientific      progress in our research and development  programs; |
|--------------------|---------------------------------------------------------------------|

| ·   | the      magnitude and scope of our research and development    programs; |
|--------------------|---------------------------------------------------------------------------|

| ·   | our      ability to establish, enforce and maintain strategic arrangements for      research, development, clinical testing, manufacturing and      marketing; |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | our      progress with preclinical development and clinical  trials; |
|--------------------|----------------------------------------------------------------------|

| ·   | the      time and costs involved in obtaining regulatory  approvals; |
|--------------------|----------------------------------------------------------------------|

| ·   | the      costs involved in preparing, filing, prosecuting, maintaining, defending      and enforcing patent claims; and |
|--------------------|-------------------------------------------------------------------------------------------------------------------------|

| ·   | the      number and type of product candidates that we  pursue.  |
|--------------------|-----------------------------------------------------------------------|

| ·   | FDA      or Institutional Review Board (IRB) objection to proposed      protocols; |
|--------------------|------------------------------------------------------------------------------------|

| ·   | discussions      or disagreement with FDA over the adequacy of trial design to potentially      demonstrate effectiveness, and subsequent design      modifications; |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | unforeseen      safety issues; |
|--------------------|--------------------------------|

| ·   | determination      of dosing issues and relatedadjustments; |
|--------------------|-------------------------------------------------------------|

| ·   | lack      of effectiveness during clinicaltrials; |
|--------------------|---------------------------------------------------|

| ·   | slower      than expected rates of patientrecruitment; |
|--------------------|--------------------------------------------------------|

| ·   | product      quality problems (e.g., sterility orpurity) |
|--------------------|----------------------------------------------------------|

| ·   | challenges      to patient monitoring and data collection during or after treatment (for      example, patients’ failure to return for follow-up visits);      and |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | failure      of medical investigators to follow our clinical  protocols. |
|--------------------|--------------------------------------------------------------------------|

| ·   | our      clinical trials may produce negative or inconclusive results, and we may      decide, or regulators may require us, to conduct additional clinical      and/or preclinical testing or to abandon  programs; |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | the      results obtained in earlier stage testing may not be indicative of results      in future trials; |
|--------------------|------------------------------------------------------------------------------------------------------------|

| ·   | trial      results may not meet the level of statistical significance required by the      FDA or other regulatory agencies; |
|--------------------|------------------------------------------------------------------------------------------------------------------------------|

| ·   | enrollment      in our clinical trials for our product candidates may be slower than we      anticipate, resulting in significantdelays; |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | we,      or regulators, may suspend or terminate our clinical trials if the      participating patients are being exposed to unacceptable health risks;      and |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | the      effects of our product candidates on patients may not be the desired      effects or may include undesirable side effects or other characteristics      that may delay or preclude regulatory approval or limit their commercial      use, if approved. |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | the      therapeutic endpoints chosen forevaluation; |
|--------------------|------------------------------------------------------|

| ·   | the      eligibility criteria defined in theprotocol; |
|--------------------|-------------------------------------------------------|

| ·   | the      size of the patient population required for analysis of the trial’s      therapeutic endpoints; |
|--------------------|----------------------------------------------------------------------------------------------------------------|

| ·   | our      ability to recruit clinical trial investigators and sites with the      appropriate competencies andexperience; |
|--------------------|--------------------------------------------------------------------------------------------------------------------------|

| ·   | our      ability to obtain and maintain patient consents;  and |
|--------------------|----------------------------------------------------------------|

| ·   | competition      for patients by clinical trial programs for other    treatments. |
|--------------------|-----------------------------------------------------------------------------------|

----

----

| ·   | the      timing of receipt of marketingapprovals; |
|--------------------|---------------------------------------------------|

| ·   | the      safety and efficacy of the potentialproducts; |
|--------------------|--------------------------------------------------------|

| ·   | the      emergence of equivalent or superior products;  and |
|--------------------|-------------------------------------------------------------|

| ·   | the      cost-effectiveness of the potentialproducts. |
|--------------------|-------------------------------------------------------|

| ·   | decreased      demand for our products; |
|--------------------|-----------------------------------------|

| ·   | injury      to our reputation and significant media  attention; |
|--------------------|-----------------------------------------------------------------|

| ·   | withdrawal      of clinical trial volunteers; |
|--------------------|-----------------------------------------------|

| ·   | costs      of litigation; and |
|--------------------|-------------------------------|

| ·   | substantial      monetary awards to plaintiffs. |
|--------------------|-------------------------------------------------|

----

| · | Approved the amendment to Article      IV of the Company’s Articles of Incorporation to change the par value of      the Company’s Common Stock  from $0.08 to      $0.001; |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| · | Approved the amendment to Article      IV of the Company’s Articles of Incorporation to authorize 25,000,000      shares of blank-check preferred stock (“Preferred      Stock”); |
|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| · | Approved the amendment to Article      I of the Company’s Articles of Incorporation to change the name of the      Company from “Edgeline Holdings, Inc.” to “Oncolin Therapeutics,      Inc.”; |
|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| · | Approved the amended and restated      articles of incorporation (“Amended & Restated Articles of      Incorporation”) in its entirety;and |
|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------|

| · | Elected Donald Picker to serve on      the Company’s board of directors until his successor is elected, appointed      and duly qualified. |
|--------|--------------------------------------------------------------------------------------------------------------------------------------------------|

----

| ITEM      5. | MARKET      FOR COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND SMALL BUSINESS ISSUER      PURCHASES OF EQUITY SECURITIES |
|--------------|--------------------------------------------------------------------------------------------------------------------------|

| Year      2008                        |   | High |   |   | Low    |   |
|---------------------------------------|--------|------|--------|--------|--------|--------|
| Quarter      ended March 31, 2008     |   | $    | 0.40   |   |   | $      | 0.39 |   |
| Quarter      ended December 31, 2007  |   | $    | 0.73   |   |   | $      | 0.30 |   |
| Quarter      ended September 30, 2007 |   | $    | 2.40   |   |   | $      | 0.40 |   |
| Quarter      ended June 30, 2007      |   | $    | 3.20   |   |   | $      | 1.60 |   |
| Year      2007                        |   | High |   |   | Low    |   |
| Quarter      ended March 31, 2007     |   | $    | 4.00   |   |   | $      | 3.20 |   |
| Quarter      ended December 31, 2006  |   | $    | 5.60   |   |   | $      | 3.20 |   |
| Quarter      ended September 30, 2006 |   | $    | 7.20   |   |   | $      | 3.20 |   |
| Quarter      ended June 30, 2006      |   | $    | 9.60   |   |   | $      | 5.60 |   |
| Year      2006                        |   | High |   |   | Low    |   |
| Quarter      ended March 31, 2006     |   | $    | 13.60  |   |   | $      | 4.00 |   |
| Quarter      ended December 31, 2005  |   | $    | 9.60   |   |   | $      | 4.00 |   |
| Quarter      ended September 30, 2005 |   | $    | 20.80  |   |   | $      | 8.80 |   |
| Quarter      ended June 30, 2005      |   | $    | 53.60  |   |   | $      | 16.00 |   |

----

| Date                | ClosingBid      Price | Volume |
|---------------------|-----------------------|--------|
| April      7, 2008  | $0.40                 | 1,600  |
| April      4, 2008  | $0.40                 | 7,195  |
| April      3, 2008  | $0.45                 | 22,074 |
| April      2, 2008  | $0.45                 | 13,250 |
| April      1, 2008  | $0.45                 | 53,109 |
| March      31, 2008 | $0.39                 | 2,000  |
| March      28, 2008 | $0.39                 | 0      |
| March      27, 2008 | $0.39                 | 0      |
| March      26, 2008 | $0.39                 | 29,049 |

----

| 1.   | a      registration statement is and remains effective for the resale of      securities in connection with the equity line of  credit; |
|----------------|-----------------------------------------------------------------------------------------------------------------------------------------|

| 2.   | at      all times during the period between the Company’s request for a drawdown      and its subsequent funding, its common stock is listed on its principal      market and shall not have been suspended from trading thereon for a period      of two consecutive trading days; |
|----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.   | the      Company has complied with its obligations and is otherwise not in breach      or default of any agreement related to the equity line of      credit; |
|----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.   | no      injunction shall have been issued and remain in force, or action commenced      by a governmental authority which has not been stayed or abandoned,      prohibiting the purchase or the issuance of securities in connection with      the equity line of credit; or |
|----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 5.   | the      issuance of the securities in connection with the equity line of credit      will not violate any shareholder approval requirements of the principal      market. |
|----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Tableof Contents

|                                                                                                                                               |   |   |   |   |
|----------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|--------|--------|
|                                                                                                                                               |   | Page   |
|                                                                                                                                               |   |   |   |   |
| Report      of Independent Registered Public Accounting Firm                                                                                       |   |   | F-2    |   |
| Consolidated      Balance Sheet as of March 31, 2008                                                                                          |   |   | F-3    |   |
| Consolidated      Statement of Operations for the period from      inception (May 9,      2007) through March 31, 2008                             |   |   | F-4    |   |
| Consolidated      Statement of Changes in Shareholders’ Deficit      for the period from inception (May 9, 2007) through March 31,      2008 |   |   | F-5    |   |
| Consolidated      Statement of Cash Flows for the period from inception (May 9, 2007)      through March 31, 2008                             |   |   | F-6    |   |
| Notes      to Consolidated Financial Statements                                                                                                    |   |   | F-7    |   |

----

----

|                                                                                                                                     |   | March 31,    2008 |       |
|------------------------------------------------------------------------------------------------------------------------------------------|--------|-------------------|------------|
|                                                                                                                                     |   |              |       |
| ASSETS                                                                                                                                   |   |              |       |
|                                                                                                                                     |   |              |       |
| Cash and cash      equivalents                                                                                                           |   | $                 | 1,174      |   |
| Prepaid      expenses                                                                                                                    |   |              | 30,750     |   |
| Deferred financing costs, net of      amortization of $2,085                                                                             |   |              | 12,915     |   |
|         Total      current assets                                                                |   |              | 44,839     |   |
| Property and equipment, net of      accumulated depreciation of $475                                                                     |   |              | 4,670      |   |
| Option agreement, net of      amortization of $8,889                                                                                     |   |              | 11,111     |   |
| Totalassets                                                                                                                              |   | $                 | 60,620     |   |
|                                                                                                                                     |   |              |       |   |
| LIABILITIES      AND SHAREHOLDERS' DEFICIT                                                                                               |   |              |       |   |
|                                                                                                                                     |   |              |       |   |
| Current      liabilities:                                                                                                                |   |              |       |   |
|     Accounts      payable, trade                                                                                     |   | $                 | 109,188    |   |
|     Accounts      payable – related party                                                                      |   |              | 111,783    |   |
|     Accrued      liabilities                                                                                         |   |              | 124,730    |   |
|     Notes      payable – related parties                                                                       |   |              | 410,000    |   |
|         Total      current liabilities                                                           |   |              | 755,701    |   |
| Shareholders'      deficit:                                                                                                              |   |              |       |   |
|     Common      stock, $.001 par value, 500,000,000 shares authorized, 42,069,533 shares      issued and outstanding |   |              | 42,069     |   |
|     Additional      paid-in capital                                                                                  |   |              | 999,530    |   |
|     Deficit      accumulated during the development stage                                                            |   |              | (1,736,680 | ) |
|          Total      shareholders’ deficit                                             |   |              | (695,081   | ) |
| Total liabilities and      shareholders' deficit                                                                                         |   | $                 | 60,620     |   |

----

|                                                                          |   | Inception (May 9, 2007) to March      31, 2008 |       |
|-------------------------------------------------------------------------------|--------|------------------------------------------------|------------|
|                                                                          |   |                                           |       |
| Revenue                                                                       |   | $                                              | --         |   |
|                                                                          |   |                                           |       |   |
| Operating      expenses:                                                      |   |                                           |       |   |
|     Compensation      and related expenses                |   |                                           | 727,445    |   |
|     Office      administration                            |   |                                           | 13,359     |   |
|     Professional      fees                                |   |                                           | 274,635    |   |
|     Investor      relations                               |   |                                           | 272,504    |   |
|     Merger      expenses                                  |   |                                           | 8,113      |   |
|     Impairment      of license agreement                  |   |                                           | 80,100     |   |
|     Acquisition      costs of subsidiary                  |   |                                           | 220,000    |   |
|     Depreciation      and amortization                    |   |                                           | 9,364      |   |
|     Other      expenses                                   |   |                                           | 105,339    |   |
|         Total      operating expenses |   |                                           | 1,710,859  |   |
|                                                                          |   |                                           |       |   |
| Interest      expense                                                         |   |                                           | 25,821     |   |
| Net loss                                                                      |   | $                                              | (1,736,680 | ) |
|                                                                          |   |                                           |       |   |
| Net loss per      share:                                                      |   |                                           |       |   |
|     Basic and      diluted                                |   | $                                              | (0.05      | ) |
|                                                                          |   |                                           |       |   |
| Weighted average number of common      shares outstanding:                    |   |                                           |       |   |
|     Basic and      diluted                                |   |                                           | 36,662,218 |   |

----

|                                                        |   |   |       |   |   |   |   |       |   |   | Deficit         |   |   |   |       |
|-------------------------------------------------------------|--------|--------|------------|--------|--------|--------|--------|------------|--------|--------|-----------------|--------|--------|--------|------------|
|                                                        |   |   |       |   |   |   |   |       |   |   | Accumulated     |   |   |   |       |
|                                                        |   |   |       |   |   |   |   | Additional |   |   | During      the |   |   |   |       |
|                                                        |   |   |       |   | Common |   |   | Paid-in    |   |   | Development     |   |   |   |       |
|                                                        |   | Shares |       |   | Stock  |   |   | Capital    |   |   | Stage           |   |   | Total  |       |
|                                                        |   |   |       |   |   |   |   |       |   |   |            |   |   |   |       |
| Issuance      of common stock for cash                      |   |   | 3,204,842  |   |   | $      | 3,205  |       |   | $      | (2,040          | )      |   | $      | -          |   |   | $ | 1,165 |   |
| Issuance      of common stock for services                  |   |   | 2,420,824  |   |   |   | 2,421  |       |   |   | (1,541          | )      |   |   | -          |   |   |   | 880 |   |
| Common      shares issued for reverse merger                |   |   | 624,334    |   |   |   | 624    |       |   |   | (624            | )      |   |   | -          |   |   |   | - |   |
| Issuance      of additional common stock in reverse merger  |   |   | 34,472,334 |   |   |   | 34,472 |       |   |   | (34,472         | )      |   |   | -          |   |   |   | - |   |
| Post-merger      capitalization                             |   |   | 40,722,334 |   |   |   | 40,722 |       |   |   | (38,677         | )      |   |   | -          |   |   |   | 2,045 |   |
| Cancellation      of common stock issued                    |   |   | (300,000   | )      |   |   | (300   | )          |   |   | 300             |   |   |   | -          |   |   |   | - |   |
| Issuance      of common stock to acquireIntertech      Bio  |   |   | 500,000    |   |   |   | 500    |       |   |   | 219,500         |   |   |   | -          |   |   |   | 220,000 |   |
| Issuance      of common stock for services                  |   |   | 600,000    |   |   |   | 600    |       |   |   | 295,400         |   |   |   | -          |   |   |   | 296,000 |   |
| Issuance      of common stock for exercise of stock options |   |   | 547,199    |   |   |   | 547    |       |   |   | 194,726         |   |   |   | -          |   |   |   | 195,273 |   |
| Issuance      of stock options for services                 |   |   | -          |   |   |   | -      |       |   |   | 328,281         |   |   |   | -          |   |   |   | 328,281 |   |
| Net      loss                                               |   |   | -          |   |   |   | -      |       |   |   | -               |   |   |   | (1,736,680 | ) |   |   | (1,736,680 | ) |
| Balance      at March 31, 2008                              |   |   | 42,069,533 |   |   | $      | 42,069 |       |   | $      | 999,530         |   |   | $      | (1,736,680 | ) |   | $ | (695,081 | ) |

----

| Cash flows from operating      activities:                                                                                  |   |    |         |
|-----------------------------------------------------------------------------------------------------------------------------|--------|---------|--------------|
|     Net      loss                                                                                       |   | $       | (1,736,680   | ) |
| Adjustments to reconcile net loss      to cash used in operating activities:                                                |   |
| Depreciation and      amortization                                                                                          |   |    | 9,364        |   |
| Amortization of deferred financing      costs                                                                               |   |    | 2,085        |   |
| Non-cash compensation expense      relating to license agreement                                                            |   |    | 119,900      |   |
| Share-based      compensation                                                                                               |   |    | 594,411      |   |
| Impairment of license      agreement                                                                                        |   |    | 80,100       |   |
| Non-cash acquisition costs of      subsidiary                                                                               |   |    | 220,000      |   |
| Changes in assets and      liabilities:                                                                                     |   |    |         |   |
| Other current      assets                                                                                                   |   |    | (15,000      | ) |
| Accounts      payable                                                                                                       |   |    | 109,188      |   |
| Accounts payable – related      parties                                                                               |   |    | 111,783      |   |
| Accrued      liabilities                                                                                                    |   |    | 124,730      |   |
| Net cash used in operating      activities                                                                                  |   |    | (380,118     | ) |
|                                                                                                                        |   |    |         |   |
| Cash flows from investing      activities:                                                                                  |   |    |         |   |
| Investment in option      agreement                                                                                         |   |    | (20,000      | ) |
| Purchase of property and      equipment                                                                                     |   |    | (5,145       | ) |
| Net cash used in investing      activities                                                                                  |   |    | (25,145      | ) |
|                                                                                                                        |   |    |         |   |
| Cash flows from financing      activities:                                                                                  |   |    |         |   |
| Proceeds from notes payable –      related parties                                                                    |   |    | 223,000      |   |
| Repayment of notes payable –      related parties                                                                     |   |    | (13,000      | ) |
| Proceeds from issuance of common      stock                                                                                 |   |    | 1,165        |   |
| Proceeds from exercise of stock      options                                                                                |   |    | 195,273      |   |
| Net cash provided by financing      activities                                                                              |   |    | 406,438      |   |
|                                                                                                                        |   |    |         |   |
| Net increase in      cash                                                                                                   |   |    | 1,174        |   |
| Cash and cash equivalents,      beginning of period                                                                         |   |    | -            |   |
| Cash and cash equivalents, end of      period                                                                               |   | $       | 1,174        |   |
|                                                                                                                        |   |    |         |   |
| Supplemental      disclosures:                                                                                              |   |    |         |   |
|     Interest      paid                                                                                  |   | $       | 3,834        |   |
|     Taxes      paid                                                                                     |   | $  | -            |   |
|                                                                                                                        |   |    |         |   |
| Non-cash financing      activities:                                                                                         |   |    |         |   |
|     Cancellation      of stock certificate                                                              |   | $       | 300          |   |
|     Issuance      of note payable for license agreement                                                 |   | $       | 200,000      |   |
|          Stock issued for prepaid investor relation services         |   | $       | 73,800  |   |

----

| 1.   | Organization      and Significant Accounting Policies |
|----------------|-------------------------------------------------------|

----

| 2.   | Property and      Equipment |
|----------------|-----------------------------|

| Office      equipment               |   | $      | 5,145 |   |
|-------------------------------------|--------|--------|-------|--------|
| Less:      accumulated depreciation |   |   | 475   |   |
|                                |   | $      | 4,670 |   |

----

| 3.   | Prepaid      Expenses |
|----------------|-----------------------|

| 4.   | Deferred      Financing Costs |
|----------------|-------------------------------|

| 5.   | Option      Agreement |
|----------------|-----------------------|

| 6.   | Accounts      Payable – Related Parties |
|----------------|-----------------------------------------------|

| 7.   | Notes      Payable – Related Parties |
|----------------|--------------------------------------------|

| 8.   | Common      Stock |
|----------------|-------------------|

----

|                                              | Before      1:80Reverse      Split | After      1:80Reverse      Split |
|---------------------------------------------------|------------------------------------|-----------------------------------|
| Common      shares for old Edgeline shareholders  | 49,946,724                         | 624,334                           |
| Initial      shares for Secure Voice shareholders | 450,053,276                        | 5,625,666                         |
| Shares      issued subsequent to STET        | 2,757,786,724                      | 34,472,334                        |
| Total      shares outstanding                     | 3,257,786,724                      | 40,722,334                        |

| 9.   | Stock      Options |
|----------------|--------------------|

|                                  |   | Number      of Shares Underlying Options |      |   | Weighted      Average Exercise Prices |   |
|---------------------------------------|--------|------------------------------------------|-----------|--------|---------------------------------------|--------|
| Outstanding      at beginning of year |   |                                     | -         |   |                                  |   | - |   |
| Granted                               |   |                                     | 2,597,199 |   |                                  | $      | 0.31 |   |
| Exercised                             |   |                                     | (547,199  | )      |                                  | $      | 0.36 |   |
| Forfeited/Expired                     |   |                                     | –   |   |                                  |   | - |   |
| Outstanding      at end of year       |   |                                     | 2,050,000 |   |                                  |   |   |   |

| As      of March 31, 2008     |   | Number      of Shares Underlying Options |      |   | Weighted      Average Exercise Prices |   |   | WEIGHTED      AVERAGE REMAINING CONTRACTUAL LIFE (YEARS) |   |   |  INTRINSIC      VALUE AS OF MARCH 31, 2008 |   |
|-------------------------------|--------|------------------------------------------|-----------|--------|---------------------------------------|--------|--------|----------------------------------------------------------|--------|--------|-------------------------------------------------|--------|
| Options      Outstanding      |   |                                     | 2,050,000 |   |                                  | $      | 0.36   |                                                     |   |   | 4.9                                             |   |   | $ | 874,886 |   |
| Options      expected to vest |   |                                     | 2,000,000 |   |                                  | $      | 0.27   |                                                     |   |   | 4.0                                             |   |   | $ | 539,861 |   |
| Options      exercisable      |   |                                     | 50,000    |   |                                  | $      | 0.27   |                                                     |   |   | 5.0                                             |   |   | $ | 13,489 |   |

----

| 10.   | Funding |
|-----------------|---------|

entered into an InvestmentAgreement with Dutchess Private Equities Fund, Ltd.(“Dutchess”).  Pursuant to this investment agreement, Dutchess shallcommit to purchase up to $10,000,000 of the Company’s common stock over thecourse of thirty-six (36) months.  The maximum amount the Company mayraise under the Investment Agreement is $10,000,000, provided it registersenough shares to raise this amount, although the Company is not obligated torequest the entire $10,000,000.  Over a period of 36 months, theCompany may periodically deliver new issue shares of its common stock toDutchess, which then delivers cash to the Company based on a price per sharetied to the current market price of its common stock.  The actualnumber of shares that the Company may issue subject to the investment agreementis not determinable as it is based on the market price of the Company’s commonstock from time to time.

| 11.   | Subsequent      Events |
|-----------------|------------------------|

----

| ITEM      8. | CHANGES      IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL      DISCLOSURE |
|--------------|------------------------------------------------------------------------------------------------|

| ITEM      8A. | MANAGEMENT'S      ANNUAL REPORT ON INTERNAL CONTROL OVER FINANCIAL  REPORTING |
|---------------|-------------------------------------------------------------------------------|

----

| Name                  | Age    | Position                                             |
|-----------------------|--------|------------------------------------------------------|
| J.      Leonard Ivins | 70     | Chief      Executive Officer and Director            |
| Donald      Picker    | 62     | President,      Chief Operating Officer and Director |
| Steven      M. Plumb  | 49     | Chief      Financial Officer                         |
|                  |   |                                                 |

----

| Name and Principal      Position                  |   | Year   |   | Salary ($) | Bonus ($) | Option Awards($) | Other Compensation      ($) | Total($) |
|---------------------------------------------------|--------|--------|--------|------------|-----------|------------------|-----------------------------|----------|
| J. Leonard      IvinsChief Executive      Officer |   |   | 2008   |       | 35,000    |  87,000     | -0-                         | -0-      | 122,000 |
| Steven M.PlumbChief Financial Officer      (1)    |   |   | 2008   |       | -0-       | -0-              | 40,454                      | -0-      | 40,454 |
| Donald PickerChief Operating      Officer         |   |   | 2008   |       | -0-       | -0-              | 512,896                     | 10,000   | 522,896 |
| Carl ChaseChief Financial      Officer(2)         |   |   | 2008   |       | -0-       | -0-              | -0-                         | 397,987  | 397,987 |

| (1)   | Mr.      Plumb has served as our Chief Financial Officer since March      2008. |
|-----------------|---------------------------------------------------------------------------------|

| (2)   | Mr.      Chase served as our Chief Financial Officer from May 2007 to March      2008. |
|-----------------|----------------------------------------------------------------------------------------|

| Name                  |   | Number of Securities Underlying      Unexercised Options (#) Exercisable |      | Number of Securities Underlying      Unexercised Options (#) Exercisable |      | Equity Incentive Plan Awards:      Number of Securities Underlying Unexercised Unearned Options      (#) |   | Option Exercise Price      ($) | Option Expiration      Date |
|-----------------------|--------|--------------------------------------------------------------------------|-----------|--------------------------------------------------------------------------|-----------|----------------------------------------------------------------------------------------------------------|--------|--------------------------------|-----------------------------|
| J. Leonard      Ivins |   |                                                                     | -0-       |                                                                     | -0-       |                                                                                                     |   | -0-                            |                        | -0- | n/a |
| Steven M.    Plumb    |   |                                                                     | 50,000    |                                                                     | 50,000    |                                                                                                     |   | -0-                            |                        | $0.10 | 3/14/2012 |
| Steven M.    Plumb    |   |                                                                     | 100,000   |                                                                     | 100,000   |                                                                                                     |   | -0-                            |                        | $0.25 | 3/14/2012 |
| Donald    Picker      |   |                                                                     | 1,600,000 |                                                                     | 1,600,000 |                                                                                                     |   | -0-                            |                        | $0.10 | 3/14/2014 |

----

| Name      and Address of Beneficial Owner (1)                                                                                    | Number      of SharesOwned |  Percentage      ofClass (2) |
|----------------------------------------------------------------------------------------------------------------------------------|----------------------------|-----------------------------------|
|     Silver      Star Holdings (3)                                                                            | 21,742,000                 | 44.8%                             |
|     Waldemar      Priebe (4)                                                                                 | 4,150,672                  | 8.5%                              |
|     Trevor      D. Ling (5)                                                                                  | 3,996,000                  | 8.2%                              |
|     Jonathan      Camarillo Trust (6)                                                                        | 3,560,000                  | 7.3%                              |
|     Danny      Chan (7)                                                                                      | 3,020,000                  | 6.2%                              |
| Officers and Directors                                                                                                           |                       |                              |
|     J.      Leonard Ivins                                                                                    | 1,600,000                  | 3.3%                              |
|     Steven      M. Plumb                                                                                     | 150,000                    | 0.3%                              |
|     Donald      Picker                                                                                       | 2,200,000                  | 4.5%                              |
|     All      directors and executive officers as      a      group (3 persons) | 3,950,000                  | 8.1%                              |

| (1)   | Unless      otherwise indicated, the mailing address of the beneficial owner is c/o      Oncolin Therapeutics, Inc., 6750 Bellaire Blvd., Suite 790, Bellaire,      Texas 77401. |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (2)   | The      percentage of beneficial ownership of Common Stock is based on 48,568,192      shares of Common Stock outstanding as of July 10, 2008 and excludes all      shares of Common Stock issuable upon the exercise of outstanding options,      other than the shares of Common Stock issuable upon the exercise of      options or warrants to purchase Common Stock held by the named person to      the extent such options or warrants are exercisable within 60 days of July      10, 2008. |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (3)   | The      business address of Silver Star Holdings is PO Box 27949, Houston, Texas      77227-7949. |
|-----------------|----------------------------------------------------------------------------------------------------|

| (4)   |  Includes      2,443,704 shares of Common Stock held by Houston Pharmaceuticals, Inc. and      50,000_shares of Common Stock held by TAK Company.  Dr. Priebe      is the controlling shareholder of Houston Pharmaceuticals, Inc. and his      wife is the sole owner of TAKCompany. |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (5)   | The      business address of Mr. Ling is 5050 Westheimer, Houston, Texas      77056. |
|-----------------|--------------------------------------------------------------------------------------|

| (6)   | The      business address of Jonathan Camarillo Trust is 5023 Polk Street, Houston,      Texas 77023. |
|-----------------|-------------------------------------------------------------------------------------------------------|

| (7)   | The      business address of Mr. Chan is 255 G Street, Suite 366, San Diego,      California 92101. |
|-----------------|-----------------------------------------------------------------------------------------------------|

----

----

| Exhibit No.                                                                                                                                                                      | Description                                                                                                                                                                                                                                                 |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   10.1*                                                                                                                                                                | Agreement      and Plan of Reorganization between Dragon Gold Resources, Inc. and Secure      Voice Communications, Inc. dated May 31, 2007.                                                                                                                |
|   10.2*                                                                                                                                                                | Dragon      Gold Resources, Inc. 2007 Stock Option Plan.                                                                                                                                                                                                    |
|   10.3*                                                                                                                                                                | Employment      agreement dated May 10, 2007, with J. Leonard Ivins                                                                                                                                                                                         |
|   10.4*      10.5***      10.6***      10.7***    10.8** | Employment      agreement dated May 10, 2007, with Carl A. Chase.Agreement      with Mr. Plumb, dated March 14, 2008Agreement      with Dr. Picker dated November 17, 2007Stock      Purchase Agreement dated March 14, 2008License      agreement with PRI |
|   21.1*                                                                                                                                                                | Subsidiaries      of the Registrant.                                                                                                                                                                                                                        |
| 31.1                                                                                                                                                                             | Certification      of J. Leonard Ivins.                                                                                                                                                                                                                     |
| 31.2                                                                                                                                                                             | Certification      of Steven M. Plumb.                                                                                                                                                                                                                      |
| 32.1                                                                                                                                                                             | Certification      for Sarbanes-Oxley Act of J. Leonard Ivins.                                                                                                                                                                                              |
| 32.2                                                                                                                                                                             | Certification      for Sarbanes-Oxley Act of Steven M.Plumb.                                                                                                                                                                                                |

----

|                             |   | 2008 |   |
|----------------------------------|--------|------|--------|
| GBH      CPAs, PC                |   | $    | 14,000 |   |
| Thomas      Leger & Co., LLP |   | $    | 20,666 |   |
| Total                            |   | $    | 34,666 |   |

----

----

| 1.   | I      have reviewed this Annual Report on Form 10-KSB of Oncolin Therapeutics,      Inc.; |
|----------------|--------------------------------------------------------------------------------------------|

| 2.   | Based      on my knowledge, this report does not contain any untrue statement of a      material fact or omit to state a material fact necessary to make the      statements made, in light of the circumstances under which such statements      were made, not misleading with respect to the period covered by this      report; |
|----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.   | Based      on my knowledge, the financial statements, and other financial information      included in this report, fairly present in all material respects the      financial condition, results of operations and cash flows of the small      business issuer as of, and for, the periods presented in this      report; |
|----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.   | I      am responsible for establishing and maintaining disclosure controls and      procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for      the small business issuer and have: |
|----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| a)   | Designed      such disclosure controls and procedures, or caused such disclosure      controls and procedures to be designed under our supervision, to ensure      that material information relating to the small business issuer, including      its consolidated subsidiaries, is made known to us by others within those      entities, particularly during the period in which this report is being      prepared; |
|----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| b)   | Paragraph      omitted in accordance with SEC transition instructions contained in SEC      Release No. 33-8238; |
|----------------|------------------------------------------------------------------------------------------------------------------|

| c)   | Evaluated      the effectiveness of the small business issuer's disclosure controls and      procedures and presented in this report our conclusions about the      effectiveness of the disclosure controls and procedures, as of the end of      the period covered by this report based on such  evaluation; |
|----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| d)   | Disclosed      in this report any change in the small business issuer's internal control      over financial reporting that occurred during the small business issuer's      most recent fiscal quarter (the small business issuer's fourth fiscal      quarter in the case of an annual report) that has materially affected, or      is reasonably likely to materially affect, the small business issuer's      internal control over financial reporting;and |
|----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 5.   | I      have disclosed, based on, my most recent evaluation of internal control      over financial reporting to the small business issuer's auditors and the      audit committee of the small business issuer's board of directors (or      persons performing the equivalentfunctions): |
|----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| a)   | All      significant deficiencies and material weaknesses in the design or      operation of internal control over financial reporting which are      reasonably likely to adversely affect the small business issuer's ability      to record, process, summarize and report financial information;      and |
|----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| b)   | Any      fraud, whether or not material, that involves management or other      employees who have a significant role in the small business issuer's      internal control over financialreporting. |
|----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 1.   | I      have reviewed this Annual Report on Form 10-KSB of Oncolin Therapeutics,      Inc.; |
|----------------|--------------------------------------------------------------------------------------------|

| 2.   | Based      on my knowledge, this report does not contain any untrue statement of a      material fact or omit to state a material fact necessary to make the      statements made, in light of the circumstances under which such statements      were made, not misleading with respect to the period covered by this      report; |
|----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.   | Based      on my knowledge, the financial statements, and other financial information      included in this report, fairly present in all material respects the      financial condition, results of operations and cash flows of the small      business issuer as of, and for, the periods presented in this      report; |
|----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.   | I      am responsible for establishing and maintaining disclosure controls and      procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for      the small business issuer and have: |
|----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| a)   | Designed      such disclosure controls and procedures, or caused such disclosure      controls and procedures to be designed under our supervision, to ensure      that material information relating to the small business issuer, including      its consolidated subsidiaries, is made known to us by others within those      entities, particularly during the period in which this report is being      prepared; |
|----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| b)   | Paragraph      omitted in accordance with SEC transition instructions contained in SEC      Release No. 33-8238; |
|----------------|------------------------------------------------------------------------------------------------------------------|

| c)   | Evaluated      the effectiveness of the small business issuer's disclosure controls and      procedures and presented in this report our conclusions about the      effectiveness of the disclosure controls and procedures, as of the end of      the period covered by this report based on such  evaluation; |
|----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| d)   | Disclosed      in this report any change in the small business issuer's internal control      over financial reporting that occurred during the small business issuer's      most recent fiscal quarter (the small business issuer's fourth fiscal      quarter in the case of an annual report) that has materially affected, or      is reasonably likely to materially affect, the small business issuer's      internal control over financial reporting;and |
|----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 5.   | I      have disclosed, based on, my most recent evaluation of internal control      over financial reporting to the small business issuer's auditors and the      audit committee of the small business issuer's board of directors (or      persons performing the equivalentfunctions): |
|----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| a)   | All      significant deficiencies and material weaknesses in the design or      operation of internal control over financial reporting which are      reasonably likely to adversely affect the small business issuer's ability      to record, process, summarize and report financial information;      and |
|----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| b)   | Any      fraud, whether or not material, that involves management or other      employees who have a significant role in the small business issuer's      internal control over financialreporting. |
|----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

----

----